异丙烯基异丙基醚 | 4188-63-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 异丙烯基异丙基醚
• 英文名称: isopropenyl isopropyl ether
• 英文别名: 2-(1-methylethoxy)propene；2-isopropoxypropylene；2-isopropoxy-propene；isopropenyl-isopropyl ether；Isopropenyl-isopropyl-aether；Isopropyl-propenylether；2-prop-1-en-2-yloxypropane
• CAS: 4188-63-0
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: MLALRMZPIVORPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  77-78.5 °C(Press: 756 Torr)
• 密度：
  0.7691 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异丙烯基异丙基醚 在 苄基三乙基氯化铵 氢氧化钾 、 sodium carbonate 作用下， 以 丙酮 为溶剂， 反应 6.0h， 生成 4-甲氧基-6-甲基-2H-吡喃酮
  参考文献：
  名称：

  Effenberger, Franz; Schoenwaelder, Karl-Heinz, Chemische Berichte, 1984, vol. 117, # 11, p. 3270 - 3279

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-3-isopropoxy-but-2-enoic acid 生成 异丙烯基异丙基醚
  参考文献：
  名称：

  The Thermal Decarboxylation of β-Alkoxycrotonic Acids. A New Synthesis of Isopropenyl Ethers

  摘要：

  DOI：

  10.1021/jo01058a028

文献信息

• POLYVINYL ETHER COMPOUND
  申请人：NAGAO Satoshi

  公开号：US20080108850A1

  公开（公告）日：2008-05-08

  The present invention provides a polyvinyl ether compound containing an alkylene glycol or polyoxyalkylene glycol unit and a vinyl ether unit in a molecule and having a molecular weight in the range of 300 to 3,000. It shows high volume resistivity and a high viscosity index, so it can be favorably used as lubricating oil for a compression refrigerator.

  本发明提供了一种聚乙烯醚化合物，其分子中含有一种烷基二醇或聚氧烷二醇单元和一种乙烯醚单元，并且分子量在300至3,000范围内。它表现出高体积电阻率和高粘度指数，因此可以优选用作压缩式制冷剂的润滑油。
• Process for the production of isopropenyl methyl ether
  申请人：——

  公开号：US20020042543A1

  公开（公告）日：2002-04-11

  Process for the production of unsaturated ethers, in particular isopropenyl methyl ether (IPM), by pyrolysis of a ketal-containing or acetal-containing mixture, in particular dimethoxypropane (DMP), in the liquid phase in the presence of an organic carboxylic acid, according to the following reaction scheme: 1 wherein R 1 =H or alkyl with 1-8 C atoms; R 2 =H, CH 3 —, C 2 H 5 —, or Cl—; R 3 =alkyl with 1-8 C atoms; R 4 =H, CH 3 —, C 2 H 5 —, or C 3 H 7 —, and R 1 and R 4 may be joined to form a 5-, 6-, or 7-membered ring. DMP is produced by the process from acetone and methanol by reaction in an acidic heterogeneous ion exchanger, the product being isolated by extraction with aqueous alkaline solution. In particular the process involves combining the IPM reaction product with the DMP reaction product, which permits the execution of a stable recycling process in which the methanol-containing streams of the IPM and DMP stages can be simultaneously extracted. The product may be isolated by the process by simple distillation of IPM from a mixture containing IPM, DMP and acetone.

  生产不饱和醚，特别是异丙烯基甲基醚（IPM）的方法，通过热解含有缩酮或醛缩合物的混合物，特别是二甲氧基丙烷（DMP），在液相中在有机羧酸的存在下，根据以下反应方案：1其中R1等于H或具有1-8个碳原子的烷基；R2等于H，CH3—，C2H5—，或Cl—；R3等于具有1-8个碳原子的烷基；R4等于H，CH3—，C2H5—，或C3H7—，并且R1和R4可以连接形成5、6或7元环。DMP是通过将丙酮和甲醇在酸性非均相离子交换剂中反应的过程生产的，产物通过用碱性水溶液萃取来分离。特别是该过程涉及将IPM反应产物与DMP反应产物结合，这允许执行稳定的循环过程，其中IPM和DMP阶段的含甲醇流可以同时被萃取。产物可以通过简单地从含有IPM、DMP和丙酮的混合物中蒸馏IPM的过程来分离。
• Tuning the stability of alkoxyisopropyl protection groups
  作者：Zehong Liang、Henna Koivikko、Mikko Oivanen、Petri Heinonen

  DOI：10.3762/bjoc.15.70

  日期：——

  of a 2’-deoxynucleoside. All studied protecting groups were readily introduced with good to excellent yields using the appropriate enol ether as a reagent and 0.5 to 1 mol % p-toluenesulfonic acid as a catalyst. The protected compounds could be purified by silica gel column chromatography without degradation. The compatibility of these protecting groups in parallel use with benzoyl and silyl groups

  引入五个不同的2-烷氧基丙烷-2-基作为2'-脱氧核苷的5'-和3'-羟基的酸不稳定的保护基。使用适当的烯醇醚作为试剂和0.5至1 mol％的对-甲氧基，很容易以高至极高的产率引入所有研究的保护基团。甲苯磺酸作为催化剂。可以通过硅胶柱色谱法纯化被保护的化合物而不会降解。验证了这些保护基与苯甲酰基和甲硅烷基并行使用的相容性。通过在HPLC溶液中跟踪它们在缓冲溶液中在25.0℃下的水解动力学，比较了不同烷氧基缩醛保护基的稳定性。在4.94至6.82的pH范围内，水解反应在水合氢离子中处于第一级。水解速率与相应的烷氧基的给电子或吸电子能力相关。研究的2-烷氧基丙烷-2-基及其从2'-脱氧胸苷的5'-羟基上裂解的相对速率常数为：环己氧基（k rel＝ 7.7），异丙氧基（7.4），甲氧基（1），苄氧基（0.6）和2,2,2-三氟乙氧基（0.04）。相同基团与3'-羟基的连接更稳定1.3到1.9倍。
• Process for preparing acetonides
  申请人：——

  公开号：US20020132837A1

  公开（公告）日：2002-09-19

  Acetonides are obtained in a one-step reaction of a carboxylic acid halide, a 1,2-aminoalcohol, and 2-alkoxypropene or 2,2-dialkoxypropane in an ether solvent and in the presence of an inorganic base. Acetonides are also obtained in a two-step reaction scheme in which an acid halide and 1,2-aminoalcohol are reacted in an ether solvent in the presence of LiOH to form a hydroxyamide, which is then reacted with 2-alkoxypropene or 2,2-dialkoxypropane in the presence of acid to form the acetonide. The acetonides resulting from the one-step and two-step protocols can be further reacted with an allylating agent such as an allyl halide in the presence of a strong base to provide the corresponding allyl acetonide. The acetonides and allyl acetonides can serve as intermediates in the production of certain HIV protease inhibitors which are useful for treating HIV infection and AIDS.

  Acetonides是通过在醚溶剂中，在无机碱的存在下，将羧酸卤、1,2-氨基醇和2-烷氧基丙烯或2,2-二烷氧基丙烷进行一步反应而获得的。Acetonides也可以通过两步反应方案获得，其中酸卤和1,2-氨基醇在醚溶剂中在LiOH的存在下反应以形成羟基酰胺，然后在酸的存在下与2-烷氧基丙烯或2,2-二烷氧基丙烷反应以形成缩醛。通过一步和两步方案得到的缩醛可以进一步与烯丙基卤等烯丙基化试剂在强碱的存在下反应，从而得到相应的烯丙基缩醛。这些缩醛和烯丙基缩醛可以作为某些用于治疗HIV感染和艾滋病的HIV蛋白酶抑制剂的生产中间体。
• Sesterterpene Compounds and Use Thereof
  申请人：Kang Heon Joong

  公开号：US20130274212A1

  公开（公告）日：2013-10-17

  The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed.

  本发明涉及七萜化合物及其在生物体内可水解的前体物或其药学上可接受的盐，以及该七萜化合物在非胰岛素依赖性糖尿病、糖尿病并发症（由糖尿病引起的肾衰竭和足溃疡）、酒精性、非酒精性和病毒性脂肪肝疾病、肥胖症、高脂血症、动脉粥样硬化、动脉粥样硬化性中风、以及脑病（帕金森病、精神分裂症和阿尔茨海默病）的预防和治疗功效方面的应用。此外，本发明还涉及功能性食品、功能性饮料、功能性化妆品和功能性饲料的组合物。